History repeats itself, and so do trends in research funding.
-
- The Scientist »
- Magazine »
- Features »
Features
Most Recent
Researchers and pharma companies have tried to attack this disease by reducing amyloid plaques, but inflammation may be the real culprit.
Whether it’s attending a Scottish dance party or asking physics buffs to custom build your tools, researchers at this year’s top institutions are getting creative at work.
Successful vaccines have been created to protect against pathogenic bacteria and viruses. Why aren’t there any for combating fungal infections?
It may be time to reconsider an AIDS vaccine which is more human than viral, triggering the immune system in a way that no other vaccine does.
A new breed of vaccines aims to wean users off cocaine.
By forging new relationships and finding novel uses for existing technologies, this year’s top companies are employing creative ways to advance their science.
Can tumors—which can originate from, and often resemble, chronically inflamed tissue—be curtailed using familiar anti-inflammatory agents, without their side effects?
Subjects
- cancer
- cell & molecular biology
- clinical trials
- disease/medicine
- drug development
- funding
- genetics & genomics
- immunology
- microbiology
- neuroscience
Sub Categories
- Bio Business
- Capsule Reviews
- Careers
- Contributors
- Critic At Large
- Editorial
- Features
- Foundations
- Lab Tools
- Modus Operandi
- Notebook
- Profile
- Reading Frames
- Scientist to Watch
- Speaking of Science
- The Literature
- Thought Experiment
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
